An BIOANALYTICAL METHOD FOR THE SIMULTANEOUS ESTIMATION OF FAVIPIRAVIR AND REMDESIVIR IN RAT PLASMA BY LCMS/MS AND ITS APPLICATION TO A PHARMACOKINETIC STUDY

Objectives: Food and drug administration approved and antiviral drugs of favipiravir and remdesivir were used in the treatment of Covid. For the bioanalytical approach of favipiravir and remdesivir, quick and easy, exact, active, and repeatable liquid chromatography-mass spectrometry (MS) MS methodology were created, employing D5-favipiravir and D5-remdesivir as internal standards. Methods: In this study, a symmetry C18 column (150 mm×4.6 mm, 3.5 μm) was used for separation, with an elution by isocracy using 0.1% formic acid in water and acetonitrile in a 50:50 v/v combination of mobile phase with 1 mL/min flow rate at room temperature. Results: Favipiravir (r2=0.9999) was tested across a reasonable concentration. According to USFDA requirements, we discovered that the medications remained stable throughout the stability trials, just because the validated approach has successfully conducting to the pharmacokinetic studies of two drugs. Conclusion: It is concluded that if both drugs are used in combination, they may produce a beneficial effect in the treatment of COVID-19 patients.